Clinical Trials Logo

Lupus Erythematosus, Discoid clinical trials

View clinical trials related to Lupus Erythematosus, Discoid.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03866317 Withdrawn - Clinical trials for Discoid Lupus Erythematosus

A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

Discoid lupus erythematosus is a chronic inflammatory skin condition and may lead to itch, skin pain, open sores, scarring, disfigurement and hair loss. Studies have shown that IL-17A may play a major role in inflammation and in the pathogenesis of discoid lupus. Treatment of discoid lupus sometimes is a challenge and unresponsive to current therapies. Secukinumab, an anti-IL-17A monoclonal antibody has been safe and effective in the treatment of psoriasis. The investigators propose to study the efficacy and safety of secukinumab in discoid lupus.

NCT ID: NCT00308204 Withdrawn - Clinical trials for Discoid Lupus Erthematosus of the Scalp

Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva

Start date: March 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the efficacy of Raptiva (efalizumab) in the treatment of discoid lupus erythematosus (DLE). Discoid lupus erythematosus is a chronic disorder, which may lead to permanent and progressive loss of hair. Lupus is a condition of chronic inflammation cause by an autoimmune disease. Autoimmune diseases are illnesses which occur when the body's tissues are attacked by its own immune system. The immune system is a complex system within the body that is designed to fight infectious agents, for example, bacteria, and other foreign invaders. One of the mechanisms that the immune system uses to fight infections is the production of antibodies. Patients with lupus produce abnormal antibodies in their blood that target tissues within their own body rather than foreign infectious agents. Lupus can cause disease of the skin, heart, lungs, kidneys, joints, and nervous system. When only the skin is involved, the condition is called discoid lupus erythematosus (DLE). Raptiva (efalizumab) is a humanized immunoglobulin(a protein extract from blood which fights off infection-sometimes called "antibody"), which targets the immune cells that are activated in inflammation. Raptiva has been approved for use in the management of psoriasis at doses of 1mg/kg, but is not approved for the treatment of DLE.

NCT ID: NCT00222183 Withdrawn - Clinical trials for Lupus Erythematosus, Cutaneous

Cutaneous Lupus Erythematosus and Elidel

Start date: June 2003
Phase: N/A
Study type: Interventional

This trial evaluates the therapeutic effect of Elidel (pimecrolimus) in comparison to the corresponding vehicle in patients with chronic discoid lupus erythematosus (dLE) or subacute cutaneous lupus erythematosus (scLE).